Arecor offers partners the opportunity to validate the capabilities of Arestat™ to stabilize their proteins, vaccines or macromolecules against agreed in vitro assays through a feasibility study. These studies typically take between 3-7 months depending on the nature of the instability, the extent of analytical development required and the type of stability trials involved. The key deliverable of the feasibility study is one or more candidate formulation(s) with required stability data.

This may be measured in terms of stability in the presence of industry-standard level of ionizing radiation for sterilization and/or accelerated shelf storage trial involving temperatures ranging from -20°C to +55°C. Upon completion of the feasibility study Arecor can transfer the technology to allow our partners to confirm the results in their own laboratories or take the formulation or product concept to the next level of development. Partnering companies are given the option to enter into a commercial license agreement at any stage during the validation program to secure access to Arestat™ formulations of their proprietary molecules.

It is the usual practice of Arecor to engage potential partners through a technical presentation and non-confidential discussion of the nature of their molecule and stability objectives. Following initial contact, should an enquiring partner desire to proceed further, confidential discussions can be held under a Confidential Disclosure Agreement (CDA) followed by the preparation of a feasibility study proposal to fit the requirements of the potential partner, outlining the scope of the work, deliverables, costs and the timeline for consideration.